ZA911471B - The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity - Google Patents

The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Info

Publication number
ZA911471B
ZA911471B ZA911471A ZA911471A ZA911471B ZA 911471 B ZA911471 B ZA 911471B ZA 911471 A ZA911471 A ZA 911471A ZA 911471 A ZA911471 A ZA 911471A ZA 911471 B ZA911471 B ZA 911471B
Authority
ZA
South Africa
Prior art keywords
pny
preparation
antagonistic activity
guanidine derivatives
pharmaceutical product
Prior art date
Application number
ZA911471A
Other languages
English (en)
Inventor
Martin C Dr Michel
C Michel Dr Martin
Johan Peter Dr Moersdorf
Peter Moersdorf Dr Johan
Heidrun Dr Engler
Engler Dr Heidrun
Helmut Dr Schickaneder
Schickaneder Dr Helmut
Kurt-Henning Dr Ahrens
Ahrens Dr Kurt-Henning
Original Assignee
Heumann Pharma Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma Gmbh & Co filed Critical Heumann Pharma Gmbh & Co
Publication of ZA911471B publication Critical patent/ZA911471B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA911471A 1990-03-30 1991-02-28 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity ZA911471B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90106200A EP0448765B1 (de) 1990-03-30 1990-03-30 Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung

Publications (1)

Publication Number Publication Date
ZA911471B true ZA911471B (en) 1991-11-27

Family

ID=8203843

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA911471A ZA911471B (en) 1990-03-30 1991-02-28 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Country Status (14)

Country Link
EP (1) EP0448765B1 (da)
JP (1) JPH0789939A (da)
KR (1) KR910016329A (da)
AT (1) ATE109979T1 (da)
AU (1) AU637882B2 (da)
CA (1) CA2037433A1 (da)
DE (1) DE59006842D1 (da)
DK (1) DK0448765T3 (da)
ES (1) ES2058651T3 (da)
HU (1) HU207945B (da)
IE (1) IE65252B1 (da)
IL (1) IL97424A (da)
PT (1) PT97138A (da)
ZA (1) ZA911471B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126212A1 (en) * 1991-12-19 1993-07-08 Albert Tseng A novel molecule which inhibits neuropeptide tyrosine biological function
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
ZA974147B (en) * 1996-05-14 1997-11-14 Novo Nordisk As Somatostatin agonists and antagonists.
ES2176776T3 (es) * 1996-08-23 2002-12-01 Agouron Pharma Ligandos del neuropeptido-y.
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
WO1998018786A1 (en) * 1996-10-31 1998-05-07 Novo Nordisk A/S Constrained somatostatin agonists and antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6144098A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
JP2000510870A (ja) * 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Ｎｐｙ５受容体アンタゴニストとしてのアミド類
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6121260A (en) 1997-07-03 2000-09-19 Neurogen Corporation Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
MXPA03002446A (es) 2000-09-20 2003-06-19 Schering Corp Imidazoles substituidos como agonistas o antagonistas duales h1 y h3 de histamina.
AU2001291040A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
ATE387439T1 (de) 2000-09-20 2008-03-15 Schering Corp Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten
DE60136284D1 (de) 2000-09-20 2008-12-04 Schering Corp Substituierte imidazole als histamine h1 und h3 agonisten oder antagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579000D1 (de) * 1985-04-02 1990-09-06 Heumann Pharma Gmbh & Co Imidazolylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
DK0448765T3 (da) 1994-09-19
HU910979D0 (en) 1991-10-28
IL97424A (en) 1995-05-26
PT97138A (pt) 1991-11-29
IE65252B1 (en) 1995-10-18
IL97424A0 (en) 1992-06-21
ES2058651T3 (es) 1994-11-01
AU637882B2 (en) 1993-06-10
KR910016329A (ko) 1991-11-05
CA2037433A1 (en) 1991-10-01
EP0448765A1 (de) 1991-10-02
EP0448765B1 (de) 1994-08-17
HU207945B (en) 1993-07-28
JPH0789939A (ja) 1995-04-04
IE910995A1 (en) 1991-10-09
ATE109979T1 (de) 1994-09-15
HUT57044A (en) 1991-11-28
DE59006842D1 (de) 1994-09-22
AU7206891A (en) 1991-10-03

Similar Documents

Publication Publication Date Title
IL97424A0 (en) Use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity
CA2122612A1 (en) Pharmaceutical products for curing tumourous diseases and process for preparing same
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
ATE163849T1 (de) Arzneimittel enthaltend als wirkstoff r-alpha- liponsäure oder s-alpha-liponsäure
HU913283D0 (en) Process for the production of hydroximethyl-(methylene-cyclopentyl)-purines and pirimidines, their medically usable salts, and of medical preparations containing them
HU912266D0 (en) Process for the production of solid medical preparations with controlled portioning of the active agents for oral use
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
HU9201937D0 (en) Aryl ethers, process for their production, and for the production of medical preparations containing them as active agents
AU1968992A (en) Preparation of fatty acid medicaments
HU9301253D0 (en) Medical preparative applicable for treatment of enlarged time of coagulation
GR3006091T3 (da)
HU913137D0 (en) 2-amino-4-carboxamido-pirimidine derivatives, their production and medical use
HU911756D0 (en) Process for the production of medical preparations containing magnesium-pyridoxal-5'-phosphate-glutaminate, for the preventing of arterial diseases
AU7454191A (en) Derivatives of glycinamide, their preparation and medicaments containing them
ATE162076T1 (de) Verwendung von nadh und nadph zur herstellung eines arzneimittels zur behandlung von morbus alzheimer
ATE170075T1 (de) Antivirales arzneimittel enthaltend prostratin
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
ATE122883T1 (de) Arzneimittel enthaltend ranitidin/wismutcarboxylat-salze.
ES2108680T3 (es) Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
HU9201358D0 (en) 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents
HU9200385D0 (en) Megacariocitopoietic factor
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
NO307126B1 (no) Anvendelse av biologisk aktive ureidoderivater for fremstilling av et medikament for bruk i behandlingen av lentivirusindusert sykdom
WO1986006960A3 (en) Use of nicorandil or pinacidil for the treatment of peripheral vascular disease
EP0651741A1 (en) DERIVATIVES OF N? G -MONOMETHYL-L-ARGININE HYDROCHLORIDE AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK.